View Past PerformanceBATM Advanced Communications バランスシートの健全性財務の健全性 基準チェック /36BATM Advanced Communicationsの総株主資本は$64.1M 、総負債は$8.7Mで、負債比率は13.6%となります。総資産と総負債はそれぞれ$113.8Mと$49.7Mです。 BATM Advanced Communicationsの EBIT は$1.9Mで、利息カバレッジ比率1.5です。現金および短期投資は$23.4Mです。主要情報13.56%負債資本比率US$8.70m負債インタレスト・カバレッジ・レシオ1.5x現金US$23.39mエクイティUS$64.11m負債合計US$49.72m総資産US$113.83m財務の健全性に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Nov 06BATM Advanced Communications Ltd., Annual General Meeting, Dec 10, 2025BATM Advanced Communications Ltd., Annual General Meeting, Dec 10, 2025. Location: the groups registered office, 4 ha harash street, nave ne eman industrial area, p o b 7318, 4524075 hod hasharon, Israelお知らせ • Oct 08Zvi Marom entered into an agreement to acquire A.M.S. 2000 Trading Impex S.r.l from BATM Advanced Communications Ltd. (LSE:BVC) for £17.6 million.DR.Zvi Marom entered into an agreement to acquire A.M.S. 2000 Trading Impex S.r.l from BATM Advanced Communications Ltd. (LSE:BVC) for £17.6 million on October 6, 2025. Under the terms of the Sale Agreement, the Group will sell AMS to Dr. Zvi Marom, a non-executive director and significant shareholder of the Group, in exchange for his entire shareholding of 96,794,500 ordinary shares of in BATM, representing c. 22.2% of the existing issued share capital. The transaction values AMS at £17.6m, based on the closing price of the Group's Ordinary Shares. Following completion, Dr. Marom will cease to be a shareholder of the Group and will resign as a director of the Group. The completion of the sale is subject to the approval of shareholders at a general meeting and and all other legal and regulatory requirements; the Board will issue a circular to convene this general meeting in due course. Mark Percy, Anita Ghanekar, James Thomas acted as advisor to BATM Advanced Communications.お知らせ • Sep 27BATM Advanced Communications Ltd. Announces Board and Committee ChangesBATM Advanced Communications Ltd. announced that Harel Locker is retiring from his position as an external director, as defined under Israeli law, of the Group with immediate effect. Mr. Locker completes his third three-year term as an external director of BATM. External directors under Israeli law are appointed for a minimum of one three-year term, which may be extended by the company (subject to shareholder approval) for no more than two additional terms of three years each. The Board will propose the appointment of a new external director for approval by shareholders at the Group's next annual general meeting. Following Mr. Locker's retirement from the Board, Prof. Varda Shalev, an external director of BATM, will assume the role of Interim Chair of the Audit Committee and a permanent chair will be appointed in due course.お知らせ • Jul 24BATM Advanced Communications Ltd. to Report First Half, 2025 Results on Aug 18, 2025BATM Advanced Communications Ltd. announced that they will report first half, 2025 results on Aug 18, 2025お知らせ • Jun 23+ 1 more updateBATM Advanced Communications Ltd. announces resignation of Ran Noy as Director, Effective 23 June 2025BATM Advanced Communications Ltd. announced that Ran Noy has resigned as Chief Financial Officer and a Director of the Group, effective 23 June 2025.お知らせ • Mar 05BATM Advanced Communications Ltd. to Report Fiscal Year 2024 Results on Mar 17, 2025BATM Advanced Communications Ltd. announced that they will report fiscal year 2024 results on Mar 17, 2025お知らせ • Dec 19BATM Approves the Appointment of Shmuel Ben Zvi as Non-Executive Director of the GroupBATM at its Annual General Meeting held on 19 December 2024, approved the appointment of Dr. Shmuel (Muli) Ben Zvi as a Non-executive Director of the Group with effect from the conclusion of the Meeting.お知らせ • Dec 12BATM Advanced Communications Limited Announces Commencement of Natslab Molecular Biology PlatformBATM Advanced Communications Limited announced that the NATlab molecular biology platform being developed by ADOR Diagnostics ("ADOR"), an associate company of the Group, has commenced pre-clinical validation at the Lazzaro Spallanzani National Institute for Infectious Diseases in Rome, Italy. This marks a key milestone in the development of NATlab and, the Group believes, will enable initial sales as well as increase industry awareness and interest from prospective partners. The advanced NATlab molecular biology platform is a point-of-care sample-to-answer solution designed to provide rapid and accurate diagnosis of infectious disease. It uses a patented isothermal amplification method for syndromic multiplex diagnostics to be able to rapidly identify a broad range of pathogens from a single test. The commencement of the pre-clinical validation phase follows the successful completion of pre-clinical trials, which were conducted at the Tzafom Medical Center in Israel, to confirm the validity of the biological process that ADOR has developed and that it can be performed within the NATlab cartridge and analyser device. NATlab identified all negative samples and had a 97% sensitivity for the positive samples, confirming the efficacy of the system and its ability to out-perform competing solutions available in the market because of its multiplex diagnostic capability for rapid and accurate diagnosis. ADOR has now made significant progress with NATlab with the full system entering the pre-clinical validation phase at the Lazzaro Sp allanzani National Institute forinfectious Diseases in Rome, a leading centre for infectious disease research and treatment. Successful completion of the pre-clinical validation is expected to enable initial sales of the NATlab and the commencement of the regulatory process under the European Union In Vitro Diagnostic Medical Device Regulation to become eligible for sale in the EU market. In addition, following the success of the pre-clinical trials, ADOR, in collaboration with the Tzafom Medical center, has received a grant from the Israel Innovation Authority to develop a NATlab panel for the diagnosis of stomach ulcers. The total value is NIS 3.4 million (c. $1 million), which is to be granted over two years based on the achievement of milestones.お知らせ • Nov 15BATM Advanced Communications Ltd., Annual General Meeting, Dec 19, 2024BATM Advanced Communications Ltd., Annual General Meeting, Dec 19, 2024. Location: the groups registered office, 4 ha harash street, nave ne eman industrial area, p o b 7318, 4524075 hod hasharon, Israelお知らせ • Aug 19BATM Advanced Communications Ltd. Provides Earnings Guidance for the Second Half of 2024BATM Advanced Communications Ltd. provided earnings guidance for the second half of 2024. For the period, the company expects increase in revenue.お知らせ • May 03BATM Advanced Communications Ltd. Selected for Tb Diagnostics ProgrammeBATM announce that the Group has been selected for aprestigious programme, that is receiving funding from the European Union, for the development of an advanced tuberculosis ("TB") diagnostics solution. The Group has also been awarded a grant of €0.5 million towards the initial 18 months of the programme with the potential for additional funding to be awarded thereafter for the next stage. The Group was selected by the National Research Council of Italy (Consiglio Nazionale delle Ricerche) ("CNR") under a competitive process involving many companies and after a lengthy and detailed verification phase to participate in the programme alongside one of CNR's research institutes, the Institute for System Analysis and Computer Science (Istituto di Analisi dei Sistemi ed Informatica) ("IASI"). The Group's participation reflects its strategy to advance the BATM diagnostics division through developing advanced molecular diagnostics solutions for substantial infectious disease markets, with the global diagnostics market for TB being worth over $2 billion. It is also demonstrative of the steps that the Group is taking to drive long-term sustainable growth through investing in constant innovation to maintain the diagnostics division's technological edge. The programme is for the development of a diagnostics system, based on the Rolling Circle Amplification ("RCA") method, for the rapid identification of TB and multi-drug resistant TB. This builds on the existing work of the BATM diagnostics division for the development of a rapid, RCA-based sample-to-answer diagnostic solution for TB and multi-drug resistant TB. The programme is receiving funding from the European Regional Development Fund via the Lazio Regional Operational Program of the Lazio regional government.お知らせ • Feb 29BATM Advanced Communications Ltd. to Report Fiscal Year 2023 Results on Mar 12, 2024BATM Advanced Communications Ltd. announced that they will report fiscal year 2023 results on Mar 12, 2024財務状況分析短期負債: BVCL.Fの 短期資産 ( $80.8M ) が 短期負債 ( $43.6M ) を超えています。長期負債: BVCL.Fの短期資産 ( $80.8M ) が 長期負債 ( $6.1M ) を上回っています。デット・ツー・エクイティの歴史と分析負債レベル: BVCL.F総負債よりも多くの現金を保有しています。負債の削減: BVCL.Fの負債対資本比率は、過去 5 年間で5.1%から13.6%に増加しました。債務返済能力: BVCL.Fの 営業キャッシュフロー はマイナスであるため、負債は十分にカバーされていません。インタレストカバレッジ: BVCL.Fの負債に対する 利息支払い は EBIT ( 1.5 x coverage) によって 十分にカバーされていません。貸借対照表健全な企業の発掘7D1Y7D1Y7D1YTech 業界の健全な企業。View Dividend企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/25 22:43終値2026/02/25 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋BATM Advanced Communications Ltd. 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。4 アナリスト機関null nullCavendishSimon StrongPeel Hunt LLPAlasdair YoungShore Capital Group Ltd1 その他のアナリストを表示
お知らせ • Nov 06BATM Advanced Communications Ltd., Annual General Meeting, Dec 10, 2025BATM Advanced Communications Ltd., Annual General Meeting, Dec 10, 2025. Location: the groups registered office, 4 ha harash street, nave ne eman industrial area, p o b 7318, 4524075 hod hasharon, Israel
お知らせ • Oct 08Zvi Marom entered into an agreement to acquire A.M.S. 2000 Trading Impex S.r.l from BATM Advanced Communications Ltd. (LSE:BVC) for £17.6 million.DR.Zvi Marom entered into an agreement to acquire A.M.S. 2000 Trading Impex S.r.l from BATM Advanced Communications Ltd. (LSE:BVC) for £17.6 million on October 6, 2025. Under the terms of the Sale Agreement, the Group will sell AMS to Dr. Zvi Marom, a non-executive director and significant shareholder of the Group, in exchange for his entire shareholding of 96,794,500 ordinary shares of in BATM, representing c. 22.2% of the existing issued share capital. The transaction values AMS at £17.6m, based on the closing price of the Group's Ordinary Shares. Following completion, Dr. Marom will cease to be a shareholder of the Group and will resign as a director of the Group. The completion of the sale is subject to the approval of shareholders at a general meeting and and all other legal and regulatory requirements; the Board will issue a circular to convene this general meeting in due course. Mark Percy, Anita Ghanekar, James Thomas acted as advisor to BATM Advanced Communications.
お知らせ • Sep 27BATM Advanced Communications Ltd. Announces Board and Committee ChangesBATM Advanced Communications Ltd. announced that Harel Locker is retiring from his position as an external director, as defined under Israeli law, of the Group with immediate effect. Mr. Locker completes his third three-year term as an external director of BATM. External directors under Israeli law are appointed for a minimum of one three-year term, which may be extended by the company (subject to shareholder approval) for no more than two additional terms of three years each. The Board will propose the appointment of a new external director for approval by shareholders at the Group's next annual general meeting. Following Mr. Locker's retirement from the Board, Prof. Varda Shalev, an external director of BATM, will assume the role of Interim Chair of the Audit Committee and a permanent chair will be appointed in due course.
お知らせ • Jul 24BATM Advanced Communications Ltd. to Report First Half, 2025 Results on Aug 18, 2025BATM Advanced Communications Ltd. announced that they will report first half, 2025 results on Aug 18, 2025
お知らせ • Jun 23+ 1 more updateBATM Advanced Communications Ltd. announces resignation of Ran Noy as Director, Effective 23 June 2025BATM Advanced Communications Ltd. announced that Ran Noy has resigned as Chief Financial Officer and a Director of the Group, effective 23 June 2025.
お知らせ • Mar 05BATM Advanced Communications Ltd. to Report Fiscal Year 2024 Results on Mar 17, 2025BATM Advanced Communications Ltd. announced that they will report fiscal year 2024 results on Mar 17, 2025
お知らせ • Dec 19BATM Approves the Appointment of Shmuel Ben Zvi as Non-Executive Director of the GroupBATM at its Annual General Meeting held on 19 December 2024, approved the appointment of Dr. Shmuel (Muli) Ben Zvi as a Non-executive Director of the Group with effect from the conclusion of the Meeting.
お知らせ • Dec 12BATM Advanced Communications Limited Announces Commencement of Natslab Molecular Biology PlatformBATM Advanced Communications Limited announced that the NATlab molecular biology platform being developed by ADOR Diagnostics ("ADOR"), an associate company of the Group, has commenced pre-clinical validation at the Lazzaro Spallanzani National Institute for Infectious Diseases in Rome, Italy. This marks a key milestone in the development of NATlab and, the Group believes, will enable initial sales as well as increase industry awareness and interest from prospective partners. The advanced NATlab molecular biology platform is a point-of-care sample-to-answer solution designed to provide rapid and accurate diagnosis of infectious disease. It uses a patented isothermal amplification method for syndromic multiplex diagnostics to be able to rapidly identify a broad range of pathogens from a single test. The commencement of the pre-clinical validation phase follows the successful completion of pre-clinical trials, which were conducted at the Tzafom Medical Center in Israel, to confirm the validity of the biological process that ADOR has developed and that it can be performed within the NATlab cartridge and analyser device. NATlab identified all negative samples and had a 97% sensitivity for the positive samples, confirming the efficacy of the system and its ability to out-perform competing solutions available in the market because of its multiplex diagnostic capability for rapid and accurate diagnosis. ADOR has now made significant progress with NATlab with the full system entering the pre-clinical validation phase at the Lazzaro Sp allanzani National Institute forinfectious Diseases in Rome, a leading centre for infectious disease research and treatment. Successful completion of the pre-clinical validation is expected to enable initial sales of the NATlab and the commencement of the regulatory process under the European Union In Vitro Diagnostic Medical Device Regulation to become eligible for sale in the EU market. In addition, following the success of the pre-clinical trials, ADOR, in collaboration with the Tzafom Medical center, has received a grant from the Israel Innovation Authority to develop a NATlab panel for the diagnosis of stomach ulcers. The total value is NIS 3.4 million (c. $1 million), which is to be granted over two years based on the achievement of milestones.
お知らせ • Nov 15BATM Advanced Communications Ltd., Annual General Meeting, Dec 19, 2024BATM Advanced Communications Ltd., Annual General Meeting, Dec 19, 2024. Location: the groups registered office, 4 ha harash street, nave ne eman industrial area, p o b 7318, 4524075 hod hasharon, Israel
お知らせ • Aug 19BATM Advanced Communications Ltd. Provides Earnings Guidance for the Second Half of 2024BATM Advanced Communications Ltd. provided earnings guidance for the second half of 2024. For the period, the company expects increase in revenue.
お知らせ • May 03BATM Advanced Communications Ltd. Selected for Tb Diagnostics ProgrammeBATM announce that the Group has been selected for aprestigious programme, that is receiving funding from the European Union, for the development of an advanced tuberculosis ("TB") diagnostics solution. The Group has also been awarded a grant of €0.5 million towards the initial 18 months of the programme with the potential for additional funding to be awarded thereafter for the next stage. The Group was selected by the National Research Council of Italy (Consiglio Nazionale delle Ricerche) ("CNR") under a competitive process involving many companies and after a lengthy and detailed verification phase to participate in the programme alongside one of CNR's research institutes, the Institute for System Analysis and Computer Science (Istituto di Analisi dei Sistemi ed Informatica) ("IASI"). The Group's participation reflects its strategy to advance the BATM diagnostics division through developing advanced molecular diagnostics solutions for substantial infectious disease markets, with the global diagnostics market for TB being worth over $2 billion. It is also demonstrative of the steps that the Group is taking to drive long-term sustainable growth through investing in constant innovation to maintain the diagnostics division's technological edge. The programme is for the development of a diagnostics system, based on the Rolling Circle Amplification ("RCA") method, for the rapid identification of TB and multi-drug resistant TB. This builds on the existing work of the BATM diagnostics division for the development of a rapid, RCA-based sample-to-answer diagnostic solution for TB and multi-drug resistant TB. The programme is receiving funding from the European Regional Development Fund via the Lazio Regional Operational Program of the Lazio regional government.
お知らせ • Feb 29BATM Advanced Communications Ltd. to Report Fiscal Year 2023 Results on Mar 12, 2024BATM Advanced Communications Ltd. announced that they will report fiscal year 2023 results on Mar 12, 2024